Deucravacitinib

Deucravacitinib (selective TYK2 inhibitor, oral) — refractory DM/JDM (open-label Phase 2)

• Trial: NCT07012057 (Phase 2)
• MOA: selective TYK2 inhibition (JAK–STAT modulation with a different selectivity profile than classic JAK1/2/3 inhibitors).
• Public results: none from this study yet (registered; outcomes pending).
• Sponsor listed as NIAMS.